Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","amount":"$440.0 million","upfrontCash":"$330.0 million","newsHeadline":"Sandoz completes acquisition of Aspen\u2019s Japanese operations, strengthening its position in world\u2019s third largest market for generics and off-patent medicines","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Biological E","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz acquires US distribution rights to two key hospital injectable medicines, reinforcing strategic focus on key growth segment","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Peptide","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Terminated Distribution and Commercialization Agreement of its SYMJEPI Products with Sandoz","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Shionogi","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Positive NICE Recommendation for Rizmoic\u00ae (naldemedine) for OIC","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aequus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Extends Commercial Agreement for Specialty Product Tacrolimus IR in Canada","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Civica Rx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Ships First Medicine in Collaboration with Civica Rx to Supply Us Hospitals","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Slayback Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Launches Generic Icatibant in U.S for Angioedema, Strategically Enhancing Injectables Portfolio","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"GSK","pharmaFlowCategory":"D","amount":"$500.0 million","upfrontCash":"Undisclosed","newsHeadline":"GSK to Sell Cephalosporin Antibiotics Business to Sandoz","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Kindeva Drug Delivery","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz in-Licenses Authorized Generic of Respiratory Medicine Proventil\u00ae HFA Inhalation Aerosol from Kindeva Drug Delivery","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"ANI Pharmaceuticals Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ANI Pharmaceuticals Expands Branded Products Portfolio Through Acquisition of Sandoz Inc. NDAs","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Begins Phase III trial of Biosimilar Targeting Wet AMD Drug Eylea","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Strengthens Pipeline by Entering Into Agreement for Biosimilar Bevacizumab, a Key Oncology Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"GSK","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Completes Acquisition of GSK\u2019s Cephalosporin Business, Reinforcing Leading Global Position in Antibiotics","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"EirGenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Submits Biologics License Application for Proposed Biosimilar Trastuzumab to US FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"December 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Authorized Generic of Narcan\u00ae (Naloxone Hydrochloride) Nasal Spray 4 mg in US to Help Reverse Opioid Overdose, Expanding Access During Surge in Overdose Deaths","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Generic Lenalidomide in 19 Countries Across Europe, Expanding Access to Essential Oncology Medicine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz, Inc. Issues Nationwide Recall of 13 Lots of Orphenadrine Citrate 100 mg Extended Release Tablets Due to Presence of a Nitrosamine Impurity","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Generic Brimonidine Tartrate\/timolol Maleate Eyedrop in Us for Patients With Ocular Hypertension, Expanding Leading Ophthalmic Portfolio","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches First Generic Pirfenidone in US for Patients With Idiopathic Pulmonary Fibrosis, Growing Its Respiratory Portfolio","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Application for Proposed Biosimilar Adalimumab\u2019s High Concentration Formulation Accepted by EMA","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Supplemental Biologics License Application Accepted by US FDA for Biosimilar Hyrimoz (adalimumab-adaz) High Concentration Formulation (HCF)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Applications for Proposed First-of-a-kind Multiple Sclerosis Biosimilar Natalizumab Accepted by US FDA and EMA","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Polpharma Biologics Announces EMA Acceptance of Marketing Authorization Application for Proposed Biosimilar Natalizumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Further Progress on its Biosimilar Pipeline, With Release of Positive Results For Denosumab Integrated Phase I\/III Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Mainbridge Health Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Liquidia Announces Collaboration to Develop a New Infusion Pump for Subcutaneous Delivery of Treprostinil Injection to Treat Pulmonary Arterial Hypertension (PAH)","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Alteogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products Enabled by Alteogen\u2019s Hybrozyme\u2122 Technology","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"Biosimilar","date":"January 2023","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz Announces Agreement to Acquire Leading Antifungal Agent Mycamine\u00ae From Astellas, Reinforcing Hospital Offering and Leading Anti-Infectives Portfolio","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives Positive Chmp Opinion for Citrate-Free High Concentration Formulation of Adalimumab Biosimilar","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Biologics License Application For Proposed Biosimilar Denosumab Accepted By US FDA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives US FDA Approval for Biosimilar Hyrimoz\u00ae (adalimumab-adaz) High-Concentration Formulation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives EC Approval For Hyrimoz High-concentration Formulation","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"April 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Adalvo","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz To Exclusively Commercialize Six Products In The Us, Reinforcing Global Leadership Position In Off-patent Medicines","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Just \u2013 Evotec Biologics","pharmaFlowCategory":"D","amount":"$640.0 million","upfrontCash":"Undisclosed","newsHeadline":"Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing","therapeuticArea":"Technology","highestDevelopmentStatus":"Undisclosed","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"Biosimilar","date":"May 2023","url1":"","url2":"","graph1":"Technology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Marketing Authorization Applications For Proposed Biosimilar Denosumab Accepted By EMA","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aequus Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed PF (Preservative Free)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Generic Treprostinil Injection Now Also Available for Subcutaneous Route of Administration to Treat PAH Patients in US","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives Positive CHMP Opinion for Multiple Sclerosis Biosimilar Natalizumab","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Announces Positive Results from Mylight Phase lll Study for Biosimilar Aflibercept","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Polpharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives FDA Approval for Tyruko (natalizumab-sztn), First and Only FDA-Approved Biosimilar for Relapsing Forms of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"August 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$62.5 million","newsHeadline":"Sandoz Completes Acquisition of Leading Antifungal Agent Mycamine\u00ae from Astellas, Reinforcing Leading Global Anti-Infectives Portfolio","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Samsung Bioepis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"EirGenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives Positive CHMP Opinion for Breast and Gastric Cancer Biosimilar Trastuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives European Commission Approval for Tyruko\u00ae (natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Executes Sandoz Spin-off, Completing Strategic Transformation into a Leading, Focused Innovative Medicines Company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Confirms Sandoz Spin-off for October 4, 2023","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"September 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"October 2023","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aequus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aequus Announces Sandoz Contract Expiry at Year End and Expected Health Canada Approval for Zimed\u00ae PF (Preservative Free)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aequus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sandoz and Aequus Agree to 1-Year Extension on Vistitan in Canada","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz launches First and Only Biosimilar for Multiple Sclerosis, Tyruko\u00ae (Natalizumab), in Germany","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"January 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Aspen Pharmacare Holdings","pharmaFlowCategory":"D","amount":"$99.9 million","upfrontCash":"Undisclosed","newsHeadline":"Aspen Concludes Two Significant Agreements with Sandoz for China and Europe","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Peptide","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Biocon Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$170.0 million","newsHeadline":"Sandoz Acquires Cimerli\u00ae Business from Coherus, Further Building Biosimilar and Ophthalmology Leadership in US Market","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"March 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Coherus Biosciences","pharmaFlowCategory":"D","amount":"$170.0 million","upfrontCash":"$170.0 million","newsHeadline":"Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Receives FDA Approval for First and Only Denosumab Biosimilars","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sandoz Launches Hyrimoz\u00ae (adalimumab) High-Concentration Formulation in Europe, Aiming to Improve Patient Care","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"Sandoz B2B","sponsor":"EirGenix","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EirGenix's Breast Cancer Biosimilar Receives Marketing Authorization by EC","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Biosimilar","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Sandoz B2B

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Wyost (denosumab) is a human monoclonal antibody and a biosimilar candidate to Prolia & Xgeva. It is a RANK ligand inhibitor, which is approved for patients with bone metastases from solid tumors.

            Lead Product(s): Denosumab

            Therapeutic Area: Oncology Product Name: Wyost

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 05, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the acquisition, Sandoz will access US biosimilar Cimerli (ranibizumab) from Coherus. Currently used in the treatment of Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, Diabetic Macular Edema.

            Lead Product(s): Ranibizumab

            Therapeutic Area: Ophthalmology Product Name: Cimerli

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: Coherus Biosciences

            Deal Size: $170.0 million Upfront Cash: $170.0 million

            Deal Type: Divestment March 04, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar product utilized in the treatment of patients diagnosed with breast cancer or metastatic stomach cancer.

            Lead Product(s): Trastuzumab

            Therapeutic Area: Oncology Product Name: Ogivri

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: Biocon Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership February 10, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Tyruko (natalizumab-sztn - biosimilar) is a highly effective anti-α4 integrin monoclonal antibody. It is indicated for the treatment of relapsing-remitting forms of multiple sclerosis.

            Lead Product(s): Natalizumab

            Therapeutic Area: Neurology Product Name: Tyruko

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 31, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the acquisition, Sandoz will access US biosimilar Cimerli (ranibizumab) from Coherus. Currently used in the treatment of Neovascular (Wet) Age-Related Macular Degeneration, Macular Edema Following Retinal Vein Occlusion, Diabetic Macular Edema.

            Lead Product(s): Ranibizumab

            Therapeutic Area: Ophthalmology Product Name: Cimerli

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: Coherus Biosciences

            Deal Size: $170.0 million Upfront Cash: $170.0 million

            Deal Type: Divestment January 22, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.

            Lead Product(s): Octreotide Acetate

            Therapeutic Area: Endocrinology Product Name: Sandostatin LAR Depot

            Highest Development Status: Approved Product Type: Peptide

            Partner/Sponsor/Collaborator: Aspen Pharmacare Holdings

            Deal Size: $99.9 million Upfront Cash: Undisclosed

            Deal Type: Agreement December 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            EG12014, biosimilar of trastuzumab, is an anti-HER2 antibody-drug conjugate (ADC) which is being developed for HER2-positive unresectable locally advanced or metastatic breast cancer (MBC).

            Lead Product(s): Trastuzumab

            Therapeutic Area: Oncology Product Name: EG12014

            Highest Development Status: Approved Product Type: Large molecule

            Recipient: EirGenix

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Hyrimoz (adalimumab-adaz) binds with specificity to TNF-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors, which is approved for rheumatic diseases, Crohn's disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa.

            Lead Product(s): Adalimumab

            Therapeutic Area: Immunology Product Name: Hyrimoz

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 21, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the spinoff, Novartis will complete its transformation to become a leading, focused medicines company and Sandoz will work on its generic and biosimilars pipeline, including SB17 a proposed biosimilar to Stelara (ustekinumab).

            Lead Product(s): Ustekinumab

            Therapeutic Area: Dermatology Product Name: SB17

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Demerger October 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Through the divestment, Novartis will complete its transformation to become a leading, focused medicines company and Sandoz will work on its generic and biosimilars pipeline, including SB17 a proposed biosimilar to Stelara (ustekinumab).

            Lead Product(s): Ustekinumab

            Therapeutic Area: Dermatology Product Name: SB17

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Demerger October 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY